Asbestosis Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Conditions:   Mesothelioma;   Malignant Mesothelioma (MM);   Early-stage Mesothelioma;   Subclinical Mesothelioma;   BRCA1-Associated Protein-1 (BAP1) Mutations;   Early-stage BAP1-associated Malignancies Intervention:   Drug: Decitabine/cedazuridine Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials